ArticleFrontiers in immunology2013
Tailoring gut immune responses with lipoteichoic acid-deficient Lactobacillus acidophilus.
Article in Frontiers in immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 27 citations in OpenAlex.
- The dual role of lipoteichoic acid: from immune modulation to therapeutic applications in disease treatment.Inflammopharmacology · 2026Review
- Comparative genome analysis of microbial strains marketed for probiotic interventions: an extension of the Integrated Probiotic Database.Microbiome research reports · 2024Article
- Do Bacteria Provide an Alternative to Cancer Treatment and What Role Does Lactic Acid Bacteria Play?Microorganisms · 2022Review
- Metagenomic profiling reveals dominance of gram-positive bacteria in the gut microbiome shifts associated with immunoglobulin A vasculitis (Henoch-Schönlein Purpura).Clinical & translational immunology · 2021Article
- Formulation technologies for oral vaccines.Clinical and experimental immunology · 2019Review
- Fermented foods and preterm birth risk from a prospective large cohort study: the Japan Environment and Children's study.Environmental health and preventive medicine · 2019Article
- Human Gut Microbiota and Gastrointestinal Cancer.Genomics, proteomics & bioinformatics · 2018Review
- SIGNing a symbiotic treaty with gut microbiota.The EMBO journal · 2015Article
- SIGNR3-dependent immune regulation by Lactobacillus acidophilus surface layer protein A in colitis.The EMBO journal · 2015Article
- Advancing the use of Lactobacillus acidophilus surface layer protein A for the treatment of intestinal disorders in humans.Gut microbes · 2015Article
- Emerging roles of lactic acid bacteria in protection against colorectal cancer.World journal of gastroenterology · 2014Review
- Lactobacillus surface layer proteins: structure, function and applications.Applied microbiology and biotechnology · 2013Review
- Microbiome, inflammation, and cancer.Cancer journal (Sudbury, Mass.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
As highlighted by the development of intestinal autoinflammatory disorders when tolerance is lost, homeostatic interactions between gut microbiota, resident immune cells, and the gut epithelium are key in the maintenance of gastrointestinal health. Gut immune responses, whether stimulatory or regulatory, are dictated by the activated dendritic cells (DCs) that first interact with microorganisms and their gene products to then elicit T and B cell responses. Previously, we have demonstrated that treatment with genetically modified Lactobacillus acidophilus is sufficient to tilt the immune balance from proinflammatory to regulatory in experimental models of colitis and colon cancer. Given the significant role of DCs in efficiently orchestrating intestinal immune responses, characterization of the signals induced within these cells by the surface layer molecules, such as lipoteichoic acid (LTA), and proteins of L. acidophilus is critical for future treatment and prevention of gastrointestinal diseases. Here, we discuss the potential regulatory pathways involved in the downregulation of pathogenic inflammation in the gut, and explore questions regarding the immune responses to LTA-deficient L. acidophilus that require future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.